Open AccessEffects of the endothelin‐converting enzyme inhibitor SM‐19712 in a mouse model of dextran sodium sulfate‐induced colitis
Author(s) -
Lee Seungjun,
Carter Patsy R.,
Watts Megan N.,
Bao Jianxiong R.,
Harris Norman R.
Publication year - 2009
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1002/ibd.20877
Subject(s) - immunostaining , colitis , inflammation , myeloperoxidase , chemistry , endocrinology , endothelin 1 , medicine , endothelin receptor , pharmacology , immunohistochemistry , receptor
Background: Ingestion by mice of dextran sodium sulfate (DSS) induces colonic vasoconstriction and inflammation, with some of the effects potentially mediated by the vasoconstrictor endothelin‐1 (ET‐1). Methods: In this study, mice given 5% 40 kD DSS for 5–6 days had elevated colonic immunostaining for ET‐1 and platelet endothelial cell adhesion molecule‐1 (PECAM‐1). Increased ET‐1 can induce microvascular constriction; however, the increase in PECAM‐1 is consistent with angiogenesis that could decrease flow resistance. Results: Our measurements of intestinal blood flow, via infused microspheres, suggests that these 2 factors may offset each other, with only a nonsignificant tendency for a DSS‐induced decrease in flow. Daily administration of the endothelin converting enzyme inhibitor SM‐19712 (15 mg/kg) attenuated DSS‐induced increases in colonic immunostaining of ET‐1 and PECAM‐1. Conclusions: SM‐19712 attenuated histologic signs of tissue injury and inflammation induced by DSS, and decreased the extent of loose stools and fecal blood. However, the inhibitor did not significantly decrease DSS‐induced colon shortening or tissue levels of myeloperoxidase (an indicator of neutrophil infiltration). (Inflamm Bowel Dis 2009)